Skip to content
2000
Volume 13, Issue 3
  • ISSN: 1874-4672
  • E-ISSN: 1874-4702

Abstract

Small interfering RNAs (siRNAs) have rapidly developed into biomedical research as a novel tool for the potential treatment of various human diseases. They are based on altered gene expression. In spite of the availability of highly active antiretroviral therapy (HAART), there is a specific interest in developing siRNAs as a therapeutic agent for human immunodeficiency virus (HIV) due to several problems including toxicity and drug resistance along with long term treatment. The successful use of siRNAs for therapeutic goals needs safe and effective delivery to specific cells and tissues. Indeed, the efficiency of gene silencing depends on the potency of the carrier used for siRNA delivery. The combination of siRNA and nano-carriers is a potent method to prevent the limitations of siRNA formulation. Three steps were involved in non-viral siRNA carriers such as the complex formation of siRNA with a cationic carrier, conjugation of siRNA with small molecules, and encapsulation of siRNA within nanoparticles. In this mini-review, the designed siRNAs and their carriers are described against HIV-1 infections both in vitro and in vivo.

Loading

Article metrics loading...

/content/journals/cmp/10.2174/1874467212666191023120954
2020-08-01
2025-05-21
Loading full text...

Full text loading...

/content/journals/cmp/10.2174/1874467212666191023120954
Loading

  • Article Type:
    Review Article
Keyword(s): cancer; delivery system; HIV infection; in vitro and in vivo studies; RNAs; siRNA
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test